Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
To assess the effect on reduction of serum phosphate and the safety of BAY77-1931 (Lanthanum
Carbonate) in patients with hyperphosphatemia undergoing hemodialysis in a randomized,
double-blind, parallel group study in comparison with Calcium carbonate.